Need Help?

Real-time response profiling through serial plasma analyses during FOLFOX treatment in patients with colorectal cancer

Response evaluation of cancer therapeutics relies on the assessment of the change in tumor burden, which is performed in accordance with defined criteria every 8-12 weeks. However, predictive factors for response are not available for the majority of patients with advanced stage colorectal cancer. Here we show that measurement of circulating tumor DNA (ctDNA) levels during one of the most commonly administered drug regimens, i.e. FOLFOX, allows an early, real-time assessment of treatment response. During the 48-hour FOLFOX application, we serially assessed plasma DNA and observed that ctDNA levels initially decreased during the first 23 hours. In patients with stable disease or partial response, ctDNA levels remained low, whereas in patients with progressive disease, ctDNA levels increased at the end of the treatment cycle predicting clinical and radiologic response correctly. Hence, ctDNA monitoring during treatment may contribute to an early outcome prediction with significant implications for the management of patients.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001006101 Illumina MiSeq NextSeq 550 52
EGAD00001006103 NextSeq 550 26
EGAD00001006104 Illumina MiSeq NextSeq 550 53
EGAD00001006105 Illumina MiSeq 27
Publications Citations
On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer.
NPJ Precis Oncol 4: 2020 30